In Vitro Activity of Tebipenem against Various Resistant Subsets of Escherichia coli Causing Urinary Tract Infections in the United States (2018 to 2020)

Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0121422. doi: 10.1128/aac.01214-22. Epub 2022 Sep 28.

Abstract

This study investigated the activity of an oral carbapenem, tebipenem, against various molecularly characterized subsets of Escherichia coli. A total of 15.0% of E. coli isolates (360/2,035 isolates) met the MIC criteria for screening for β-lactamases. Most of those isolates (74.7% [269/360 isolates]) carried blaCTX-M. The CTX-M distribution varied (50% to 86%) among Census Regions, as did that of plasmid AmpC genes (up to 41% among E. coli isolates from the New England Region). Tebipenem and intravenous carbapenems showed uniform activity against various E. coli subsets.

Keywords: CTX-M; ESBL; ST131; carbapenems; oral; resistance; surveillance.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Carbapenems / pharmacology
  • Escherichia coli / genetics
  • Escherichia coli Infections* / drug therapy
  • Escherichia coli Proteins* / genetics
  • Humans
  • United States
  • Urinary Tract Infections* / drug therapy
  • beta-Lactamases / genetics

Substances

  • tebipenem
  • Anti-Bacterial Agents
  • Carbapenems
  • beta-Lactamases
  • Escherichia coli Proteins